Oppenheimer Initiates Coverage of Vanda Pharmaceuticals with an Outperform Rating
Published . Updated .
Fintel reports that on September 23, 2026, Oppenheimer initiated coverage of Vanda Pharmaceuticals (NASDAQGM:VNDA) (DB:VM4) with a Outperform recommendation.Prior to this coverage initiation, the stock closed at $5.21 on September 22, 2026. This latest close represents a one-week
Directly affected
- VNDA Vanda Pharmaceuticals
Named in this report.
Indirectly affected
- UPGD INVESCO BLOOMBERG ANALYST RATING ETF
GA selected UPGD as a RELATED security because its canonical security name directly matches this event's themes: rating. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- XPH STATE STREET SPDR S&P PHARMACEUTICALS ETF
GA selected XPH as a RELATED security because its canonical security name directly matches this event's themes: pharmaceuticals. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Fintel reports that on September 23, 2026, Oppenheimer initiated coverage of Vanda Pharmaceuticals (NASDAQGM:VNDA) (DB:VM4) with a Outperform recommendation.Prior to this coverage initiation, the stock closed at $5.21 on September 22, 2026…
Source: Nasdaq Markets
How far Vanda Pharmaceuticals (VNDA) has moved since 23 Sep 2026
Since the first closing price after “Oppenheimer Initiates Coverage of Vanda Pharmaceuticals with an Outperform Rating,” Vanda Pharmaceuticals (VNDA) is -18.24%. The S&P 500 fund (SPY) is -0.09% over the same days, a -18.15% difference versus the market.
Who gains and who loses around Vanda Pharmaceuticals (VNDA)
Companies mentioned with this story
- VNDA Vanda Pharmaceuticals
In “Oppenheimer Initiates Coverage of Vanda Pharmaceuticals with an Outperform Rating,” Vanda Pharmaceuticals (VNDA) is linked, with no stored direction, medium confidence. Reason on file: GA selected VNDA as a RELATED security because its canonical security name directly matches this event's themes: pharmaceuticals, vanda. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- UPGD Invesco Bloomberg Analyst Rating Etf
Invesco Bloomberg Analyst Rating Etf (UPGD) is linked, with no stored direction, medium confidence in the 23 Sep 2026 story “Oppenheimer Initiates Coverage of Vanda Pharmaceuticals with an Outperform Rating.” Reason on file: GA selected UPGD as a RELATED security because its canonical security name directly matches this event's themes: rating. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- XPH State Street Spdr S&P Pharmaceuticals Etf
State Street Spdr S&P Pharmaceuticals Etf (XPH) is linked, with no stored direction, medium confidence in the 23 Sep 2026 story “Oppenheimer Initiates Coverage of Vanda Pharmaceuticals with an Outperform Rating.” Reason on file: GA selected XPH as a RELATED security because its canonical security name directly matches this event's themes: pharmaceuticals. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Vanda Pharmaceuticals (VNDA)
“Oppenheimer Initiates Coverage of Vanda Pharmaceuticals with an Outperform Rating” (23 Sep 2026) reaches Vanda Pharmaceuticals (VNDA) through this story.
The link for Vanda Pharmaceuticals (VNDA) is this: GA selected VNDA as a RELATED security because its canonical security name directly matches this event's themes: pharmaceuticals, vanda. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Invesco Bloomberg Analyst Rating Etf (UPGD) is here too. Its reason reads: GA selected UPGD as a RELATED security because its canonical security name directly matches this event's themes: rating. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Price levels for Vanda Pharmaceuticals (VNDA)
UPGD traded between 80.14 and 82.00 across 17 sessions. The latest close on file is 82.00. VNDA traded between 4.00 and 5.32 across 20 sessions. The latest close on file is 4.08. XPH traded between 61.54 and 68.95 across 20 sessions. The latest close on file is 62.24.
How strong the case is around Vanda Pharmaceuticals (VNDA)
27 out of 100
“Oppenheimer Initiates Coverage of Vanda Pharmaceuticals with an Outperform Rating” scores 27 out of 100. The score uses 1 sources, and 3 linked companies.